Skip to content

Inspection Record

XeCare LLC — FDA 483 Findings

US FDAInspected 2026-06-17Published 2026-09-10 3 findingsOther quality systemContamination controlMaterial and supplier control

Inspectors Kara J Wright · Logan T WilliamsThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

Use of ingredients not intended for pharmaceutical use in non-sterile drug production.

2Contamination control

Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

3Material and supplier control

Materials were exposed to lower than ISO 5 quality air.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-09-10. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

XeCare LLC company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.